Adial Pharmaceuticals advances second cohort in PK study of AD04

Adial Pharmaceuticals announced the progression to the second cohort in the pharmacokinetics, PK, study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, AUD, in heavy drinking patients, following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial commented, “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.”